Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,155 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Anemia
Interventions: Lenalidomide, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Centralia, Illinois • Lebanon, New Hampshire + 4 more

Conditions: Diabetic Macular Edema (DME)
Interventions: Remigromig, Ranibizumab; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 107
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more

Conditions: Prostate Carcinoma
Interventions: Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 115
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 88 more

Conditions: Oncology, Solid Tumor, Adult
Interventions: Caris Molecular Intelligence Profile; Diagnostic Test
Lead sponsor: Caris Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Fayetteville, Arkansas • Omaha, Nebraska • San Antonio, Texas

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 32
States / cities: Peoria, Arizona • Los Angeles, California • North Hollywood, California + 27 more

Conditions: Breast Cancer
Interventions: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 39
States / cities: Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more

Conditions: Normal Healthy Eyes
Interventions: No intervention required; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Glargine Injection, Lantus®; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more

Conditions: Solid Tumors
Interventions: GO-203-2c; Drug
Lead sponsor: Genus Oncology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 1 more

Conditions: Advanced Solid Tumor
Interventions: GS-5319, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Boston, Massachusetts • New Brunswick, New Jersey • San Antonio, Texas + 1 more

Conditions: Prostate Cancer
Interventions: bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate; Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 75
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Bevacizumab, Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium, Questionnaire Administration, Vinorelbine Tartrate; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 1139
States / cities: Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 712 more

Conditions: Carcinoma
Interventions: Everolimus, Everolimus Placebo, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more

Conditions: Osteoarthritis
Interventions: SD-6010, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 1,457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 120
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 83 more

Conditions: Osteomyelitis Tibia, Tibial Fractures, Open Tibia Fracture
Interventions: Antibiotic coated intramedullary Nail, Standard Intramedullary Nail; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Gainesville, Florida • Temple Terrace, Florida • Macon, Georgia + 12 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more

Conditions: Peripheral Arterial Occlusive Disease
Interventions: PAD endovascular treatments; Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 52
States / cities: Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 5,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1435
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more

Conditions: Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions: bleomycin sulfate, filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older · Male only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 149
States / cities: Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more

Conditions: Cancer Survivorship
Interventions: Conexiones, Taking Time; Behavioral
Lead sponsor: New Mexico State University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Las Cruces, New Mexico • El Paso, Texas • San Antonio, Texas

Conditions: PTSD - Post Traumatic Stress Disorder
Interventions: Live workshop, AI-enhanced Web-based training, Consultation video calls, TherapyTrainer; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza, Human
Interventions: Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 45,789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 263
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 192 more

Conditions: Cocaine Dependence
Interventions: vigabatrin, placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • San Francisco, California • Torrance, California + 8 more

Conditions: Cancer of Breast
Interventions: Rapamycin; Drug
Lead sponsor: LuZhe Sun; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

POA Retrospective Repository

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Staining in a Healthy, Non-Dry Eye Population

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

Taking Time to Connect: A Study of Programs for Hispanic Mothers Diagnosed With Cancer and Their Children

Advancing Skills Through Consultation, Education, and Novel Technologies

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Vigabatrin for Treatment of Cocaine Dependence

Aging Mammary Stem Cells and Breast Cancer Prevention